• Apex OZ CJC-1295 (No DAC) and Ipamorelin blend 10mg vial
FOR RESEARCH PURPOSES ONLY

CJC-1295 (No DAC) + Ipamorelin Blend 10mg

$84.99
$84.99
Sale Sold out
Tax included. Shipping calculated at checkout.

Order now
  • ≥99% Purity
  • Secure Payments
  • Express Shipping
View full details

CJC-1295 (No DAC) combined with Ipamorelin is a dual-peptide blend studied in laboratory environments for its interaction with growth hormone-related signalling pathways. This combination is commonly utilised in controlled research settings to explore peptide synergy, receptor activity, and endocrine response mechanisms.

Apex OZ supplies this 5mg blend in a high-purity, lyophilised format, designed to ensure stability, accuracy, and consistency across experimental applications. Each batch is manufactured under strict quality-controlled conditions, supporting reliable and repeatable outcomes in professional research environments.

IDENTITY & CONTENT — CJC-1295 (No DAC) + Ipamorelin Blend 10mg

This batch was analysed by Janoshik Analytical for our manufacturing partner and supplied to us.

CJC-1295 (mod GRF 1–29)5.88 mg
Ipamorelin5.21 mg
Apex OZ refAOZ-CI-0326
AnalysedMar 2026

Reports supplied to us by our manufacturing partner are not published, and their reference numbers are withheld, as we are not able to identify that partner. Quote the Apex OZ reference above and we can confirm which analysis applies to your vial.

For research purposes only — not for human or veterinary use

Key Features

  • ≥99% purity (HPLC tested)
  • 10mg combined peptide blend
  • CJC-1295 (No DAC) + Ipamorelin formulation
  • Lyophilised powder for enhanced stability
  • Suitable for endocrine and receptor-based research

Product Specifications

  • Peptides: CJC-1295 (No DAC) + Ipamorelin
  • Quantity: 10mg
  • Purity: ≥99% (HPLC)
  • Form: Lyophilised powder
  • Structure: Dual-peptide blend
  • Storage: Store at 2–8°C, protected from light and moisture

Intended Use

This product is supplied strictly for laboratory research purposes. Intended for in vitro use in controlled scientific environments by qualified professionals.

Compliance & Safety Notice

This compound is not intended for human or animal consumption and must not be used for therapeutic, diagnostic, cosmetic, or food-related purposes.

By purchasing, you confirm that you are a qualified researcher or authorised to act on behalf of a licensed research facility, and that all use complies with applicable regulations. No claims are made regarding safety, efficacy, or intended outcomes.

  • EXPRESS SHIPPING

    Express shipping with tracking. We also offer free shipping for orders over $400.

  • HIGH QUALITY RESEARCH PEPTIDES

    Independent laboratory analysis published for tested batches

  • SUPPORT AVAILABLE

    If you require support or have a question, reach out to the team today.

  • 100% SECURE PAYMENT

    We accept all major providers including Visa, Mastercard, Amex, PayPal.

FAQ's

These are some of the most commonly asked questions we get. If you have a question, please go through these first before reaching out - more than likely the questions has already been answered!

Contact us

Have a question?

support@apexoz.com
Our average response time is 24 hours.

This product combines two peptides:

  • CJC-1295
  • Ipamorelin

The blend brings CJC-1295 (No DAC) and Ipamorelin together so researchers can study the two peptides in the same research setting, including their interaction with related signalling pathways.

The phrase “No DAC” means the CJC-1295 used in this product does not contain the Drug Affinity Complex (DAC). This will help researchers in choosing efficiently. 

The blend is used in relation to research involving growth hormone-related signalling, receptor activity, endocrine mechanisms, as well as peptide interactions.

Endocrine research looks at hormones and the signalling systems connected with them. This blend is ideal for research involving endocrine response mechanisms.

The batch has been analysed by Janoshik Analytical for the manufacturing partner, with the results supplied to Apex OZ. The March 2026 analysis reports 5.88mg of CJC-1295 (mod GRF 1–29) and 5.21mg of Ipamorelin for the tested sample, under Apex OZ reference AOZ-CI-0326.